#SFHS2613501AFrance updates reimbursable medicines list for weight-management treatments
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The order adds six pharmaceutical products to France’s list of medicines reimbursed by social health insurance, but only for tightly defined weight-management uses. Coverage applies to adults whose structured nutritional care has not worked, and only alongside a low-calorie diet and increased physical activity. Patients are eligible mainly if they have very severe obesity, or severe obesity with listed health conditions such as type 2 diabetes, treated high blood pressure, sleep apnea, chronic kidney disease, NASH or liver fibrosis, fertility-related issues, severe obesity-related asthma, disabling joint or back conditions, or other specified complications. Healthcare providers and insurers will need to apply these eligibility rules when prescribing or approving reimbursement.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds six pharmaceutical products to the reimbursable medicines list for insured patients in France
- Limits reimbursement to adult weight-management cases after failed structured nutritional care
- Defines BMI thresholds and qualifying obesity-related comorbidities for coverage
Obligations
What this law requires
Limit social health insurance reimbursement for the listed pharmaceutical specialties to adult weight-management treatment only where a well-conducted nutritional intervention has failed, defined as less than 5% weight loss after six months.
Prescribe or approve reimbursement for the listed weight-management medicines only as an adjunct to a low-calorie diet and increased physical activity.
Allow reimbursement without comorbidity only for adult patients whose initial BMI is at least 40 kg/m².
For adult patients with initial BMI of at least 35 kg/m², allow reimbursement only if the patient has at least one listed comorbidity, such as type 2 diabetes, treated hypertension, qualifying hypertriglyceridemia, NASH or hepatic fibrosis, polycystic ovary syndrome, fertility issues linked to an assisted reproduction project, chronic kidney disease, Child A cirrhosis, obstructive sleep apnea-hypopnea syndrome, severe obesity-related asthma, disabling chronic back pain or osteoarthritis, or disabling urinary incontinence.
For chronic kidney disease cases, obtain a nephrologist’s opinion before reimbursement approval, and for severe or end-stage renal insufficiency with a kidney-transplant project, discuss the decision case by case with the transplant team and manage it in centers with a dialysis structure.